What is the difference between PPCM and the normal heart changes of pregnancy?

During a healthy pregnancy, the heart adapts by increasing cardiac output and heart rate, which can cause mild breathlessness and reduced exercise tolerance — these are normal and reversible. PPCM involves a pathological drop in heart muscle function, with the ejection fraction falling below 45% and the heart chambers enlarging. An echocardiogram can clearly distinguish between normal pregnancy-related cardiac changes and PPCM, and is the key test when symptoms are concerning.

Approximately 50–70% of women with PPCM recover normal or near-normal cardiac function within 6 to 12 months with appropriate treatment. Recovery is most likely in women with milder initial dysfunction (LVEF closer to 45%), those diagnosed and treated early, and those who receive bromocriptine alongside standard heart failure therapy. Women who do not recover fully require ongoing cardiac management and careful counselling before any future pregnancy.

Is breastfeeding safe if I have PPCM?

Breastfeeding is generally not recommended for women receiving bromocriptine, since the drug works by suppressing prolactin and milk production. Several standard heart failure medications used in PPCM — including ACE inhibitors — are also not compatible with breastfeeding. The decision should be made individually with the cardiology and obstetric team. In women not receiving bromocriptine and using medications confirmed safe for lactation, breastfeeding may be possible in some cases.

Can PPCM happen again in a future pregnancy?

Yes. Women who have had PPCM face a recurrence risk of 20–30% in subsequent pregnancies, even after full cardiac recovery. In women who have not recovered full cardiac function, the risk of severe deterioration and death in a subsequent pregnancy is substantially higher. All women with a history of PPCM should receive pre-pregnancy counselling from a cardiologist specialising in cardiac conditions in pregnancy before attempting another pregnancy.

How is PPCM different from pre-eclampsia?

Pre-eclampsia is a condition of high blood pressure and organ damage — primarily affecting the kidneys and liver — that develops during pregnancy, and does not necessarily involve cardiac failure. PPCM is specifically a heart muscle disease resulting in reduced cardiac function, defined by an LVEF below 45%. The two conditions can coexist, and pre-eclampsia is a recognised risk factor for PPCM. Both require urgent management, but treatment approaches differ; an echocardiogram is needed to assess cardiac function whenever PPCM is suspected alongside pre-eclampsia.

Peripartum cardiomyopathy — Glossary

What it is

Peripartum cardiomyopathy (PPCM) is a rare, potentially life-threatening form of heart failure affecting approximately 1 in 1,000 to 1 in 4,000 pregnancies, arising in the final month of pregnancy or within five months of delivery in women with no prior history of heart disease. Also called pregnancy-associated cardiomyopathy or postpartum cardiomyopathy, PPCM is a form of dilated cardiomyopathy — a condition in which the heart muscle weakens and the chambers enlarge, reducing the heart's ability to pump blood effectively. Diagnosis requires a left ventricular ejection fraction (LVEF) below 45% with no other identifiable cause.

Roughly 50–70% of women recover normal or near-normal cardiac function within 6 to 12 months of diagnosis. The remainder develop chronic heart failure, and mortality in high-income countries — including Canada — ranges from 2 to 10%, higher where specialist access is delayed. PPCM is more common in women of African descent, those over 30, women carrying multiples, and those with pre-eclampsia or gestational hypertension. No dedicated Canadian prevalence registry exists, but Canadian rates are assumed to track the 1 in 1,000–4,000 range reported in U.S. and European cohorts.

Causes and mechanism

The exact cause of PPCM remains incompletely understood. Several overlapping mechanisms are thought to contribute:

Prolactin toxicity: Prolactin rises sharply in late pregnancy and during breastfeeding. The enzyme cathepsin D cleaves prolactin into a 16 kDa fragment that is directly toxic to cardiac cells, impairing function and promoting inflammation. This mechanism, first described by Hilfiker-Kleiner et al. (2007), is the basis for bromocriptine therapy.
Oxidative stress: The physiological demands of late pregnancy increase oxidative stress, which may activate cathepsin D and trigger the damaging prolactin cleavage.
Antiangiogenic signalling: Elevated sFlt-1 (soluble fms-like tyrosine kinase 1), a factor that suppresses blood vessel formation, is seen in pre-eclampsia and has been implicated in PPCM pathogenesis.
Autoimmune response: Fetal cells entering maternal circulation may trigger an immune response against cardiac proteins in susceptible individuals.
Genetic predisposition: Mutations in genes associated with familial dilated cardiomyopathy — particularly TTN (titin) — are found in a meaningful proportion of PPCM cases, suggesting an underlying genetic vulnerability unmasked by pregnancy.

Key risk factors at a glance:

Risk factor	Notes
African ethnicity	Higher incidence and worse outcomes reported
Age over 30	Risk increases with maternal age
Pre-eclampsia / gestational hypertension	Also elevates sFlt-1
Multiple gestation (twins or more)	Greater haemodynamic load
Multiparity	Risk increases with number of prior pregnancies
Family history of cardiomyopathy	Suggests shared genetic susceptibility
Malnutrition	Reported in lower-income settings

Symptoms and diagnosis

PPCM symptoms overlap substantially with normal late-pregnancy changes, which is why diagnosis is often delayed. Symptoms that warrant cardiac investigation include:

Progressive shortness of breath, especially when lying flat (orthopnoea) or on exertion
Waking suddenly at night unable to breathe (paroxysmal nocturnal dyspnoea)
Leg and ankle swelling more severe than typical pregnancy oedema
Persistent cough or wheeze
Fatigue well beyond expected pregnancy or postnatal tiredness
Palpitations, irregular heartbeat, or chest tightness

Diagnostic workup:

Echocardiogram — the definitive test; confirms LVEF below 45% and chamber dilation. Available at most Canadian hospitals and through cardiology referral.
BNP or NT-proBNP — elevated in heart failure; useful for rapid triage in emergency or obstetric settings.
ECG — may show arrhythmias or non-specific changes.
Chest X-ray — may reveal cardiomegaly and pulmonary oedema.
Cardiac MRI — used selectively for detailed structural assessment.
Exclusion of other causes — infection, valvular disease, and pre-existing cardiomyopathy must be ruled out before PPCM is confirmed.

Treatment options

PPCM requires prompt specialist management, typically involving cardiology and maternal-fetal medicine working together.

Standard heart failure therapy:

Diuretics (furosemide): relieve fluid overload and breathlessness.
Beta-blockers (carvedilol, metoprolol): reduce heart rate and cardiac workload; improve long-term function.
ACE inhibitors or ARBs: reduce afterload and support recovery. Contraindicated during pregnancy due to fetal toxicity; safe postpartum.
Hydralazine and nitrates: used as ACE inhibitor alternatives during pregnancy.
Anticoagulation: recommended when LVEF falls below 35%, given the high thrombus risk in a dilated, poorly contracting ventricle.

Prolactin-targeted therapy:

Bromocriptine: a dopamine agonist that suppresses prolactin production. Evidence from South African randomised trials suggests it improves cardiac recovery in PPCM and it is increasingly used in specialist centres. Bromocriptine requires cessation of breastfeeding and should be initiated under cardiology supervision.

Monitoring: Serial echocardiograms every 1–3 months track recovery. Cardiac medications are continued until full recovery is confirmed, then gradually weaned under specialist guidance.

When to see a clinician in Canada

Seek urgent care — go to an emergency department or call 911 — if you are in the last month of pregnancy or within five months of delivery and experience any of the following:

Sudden or worsening shortness of breath, particularly when lying down
Waking at night unable to breathe
Rapidly worsening leg swelling
Palpitations, chest tightness, or chest pain
Extreme fatigue or faintness that feels out of proportion

These symptoms are easy to attribute to normal pregnancy or postpartum recovery. If a clinician suspects cardiac involvement, an echocardiogram is a non-invasive test that can confirm or exclude PPCM quickly. In Canada, echocardiography is available through hospital emergency departments and cardiology referral; LifeLabs and Dynacare process BNP/NT-proBNP blood tests that can support rapid triage. Women with a prior PPCM diagnosis should seek pre-pregnancy counselling from a cardiologist with expertise in cardiac conditions in pregnancy before attempting another pregnancy — this service is available at most Canadian academic cardiac centres.

Limitations and open questions

Research is still emerging on several aspects of PPCM. The relative contribution of prolactin toxicity, antiangiogenic signalling, and genetic susceptibility has not been fully resolved, and no single mechanism explains all cases. Evidence for bromocriptine comes primarily from trials conducted in South Africa; large randomised controlled trials in North American and European populations are limited, and Health Canada has not issued specific guidance on bromocriptine use in PPCM. The optimal duration of cardiac medication after recovery is not established by high-quality evidence. It is also unclear whether women who recover full cardiac function face the same long-term cardiovascular risk as the general population, or whether PPCM leaves a lasting subclinical vulnerability. Canadian-specific incidence data and outcomes registries are lacking, meaning clinicians rely on international figures that may not fully reflect the Canadian obstetric population. Genetic testing for TTN and related variants is not yet standard of care in Canada for PPCM workup, though practice is evolving.

Peripartum cardiomyopathy